Article Text

  1. J M Hascoet1,
  2. C Hubert1,
  3. C Boschat3,
  4. F Rochat3,
  5. B Namour2,
  6. S Emady-Azar3,
  7. J Benyacoub3,
  8. P Steenhout4
  1. 1Maternite Regionale Universitaire, Nancy, France
  2. 2CHU, Nancy, France
  3. 3Nestle Research Center, Lausanne, Switzerland
  4. 4Nestle Nutrition, Nestec Ltd, Vevey, Switzerland


Objective To assess the effect of a formula with a composition close to human milk, Nan containing or not a probiotic, Bifidobacterium longum (BL999; Morinaga, Japan), on early life microbiota and immune development as compared to a standard control formula.

Methods Randomized, double blind, controlled trial of 3 groups: control formula (n = 33); Nan: 30/70 Casein/Whey ratio, low proteins (1.8 g/100 Kcal); low phosphate (31 mg/100 Kcal) and high lactose levels (11.1 g/100 Kcal) (n = 30); Nan + BL999 (n = 28) and a reference Breast Fed group (BF, n = 35). Healthy singleton term infants received the study formula for 4 months. Primary outcome was stool bifidobacteria counts (log CFU/g: Median [IQR]) at 2 months of age. Secondary outcome was the analysis of stool IgA levels (μg/mL) at 2 months.

Results Bifidobacteria counts were significantly higher for BF (10[0.9]), Nan (10.0[0.8]) or Nan +BL999 (9.8[1.4]) groups than control (9.2[3.5], p<0.01). Both Nan alone or with BL999 tended to promote higher production of fecal IgA than controls (33[32] and 42[35] vs. 22[17] respectively, p = 0.07), closer to BF (53[37]).

Conclusions These data show that infant formulae Nan with or without BL999 have similar bifidogenic effect than BF. Both Nan +/− BL999 tended to enhance immune functions compared to standard formula.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.